Logo image of AVDL

AVADEL PHARMACEUTICALS (AVDL) Stock Fundamental Analysis

NASDAQ:AVDL - Nasdaq - IE00BDGMC594 - Common Stock - Currency: USD

7.91  +0.03 (+0.38%)

After market: 7.91 0 (0%)

Fundamental Rating

4

Taking everything into account, AVDL scores 4 out of 10 in our fundamental rating. AVDL was compared to 192 industry peers in the Pharmaceuticals industry. AVDL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AVDL shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AVDL had negative earnings in the past year.
AVDL had a negative operating cash flow in the past year.
In the past 5 years AVDL reported 4 times negative net income.
In the past 5 years AVDL always reported negative operating cash flow.
AVDL Yearly Net Income VS EBIT VS OCF VS FCFAVDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -29.73%, AVDL is in line with its industry, outperforming 54.17% of the companies in the same industry.
AVDL's Return On Equity of -66.13% is in line compared to the rest of the industry. AVDL outperforms 51.04% of its industry peers.
Industry RankSector Rank
ROA -29.73%
ROE -66.13%
ROIC N/A
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVDL Yearly ROA, ROE, ROICAVDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

AVDL has a Gross Margin of 90.97%. This is amongst the best in the industry. AVDL outperforms 93.75% of its industry peers.
AVDL's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for AVDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
AVDL Yearly Profit, Operating, Gross MarginsAVDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

AVDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AVDL has more shares outstanding
Compared to 5 years ago, AVDL has more shares outstanding
There is no outstanding debt for AVDL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVDL Yearly Shares OutstandingAVDL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AVDL Yearly Total Debt VS Total AssetsAVDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

AVDL has an Altman-Z score of -1.21. This is a bad value and indicates that AVDL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.21, AVDL perfoms like the industry average, outperforming 47.40% of the companies in the same industry.
AVDL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.21
ROIC/WACCN/A
WACC7.43%
AVDL Yearly LT Debt VS Equity VS FCFAVDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

AVDL has a Current Ratio of 2.75. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AVDL (2.75) is comparable to the rest of the industry.
AVDL has a Quick Ratio of 2.33. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.33, AVDL perfoms like the industry average, outperforming 49.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.75
Quick Ratio 2.33
AVDL Yearly Current Assets VS Current LiabilitesAVDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

7

3. Growth

3.1 Past

AVDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.13%, which is quite impressive.
AVDL shows a strong growth in Revenue. In the last year, the Revenue has grown by 504.79%.
The Revenue has been growing by 23.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)74.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.76%
Revenue 1Y (TTM)504.79%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%159.14%

3.2 Future

AVDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.24% yearly.
The Revenue is expected to grow by 26.01% on average over the next years. This is a very strong growth
EPS Next Y115.52%
EPS Next 2Y82.67%
EPS Next 3Y88.5%
EPS Next 5Y46.24%
Revenue Next Year48.16%
Revenue Next 2Y40.08%
Revenue Next 3Y33.31%
Revenue Next 5Y26.01%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
AVDL Yearly Revenue VS EstimatesAVDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
AVDL Yearly EPS VS EstimatesAVDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

AVDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 98.00, AVDL can be considered very expensive at the moment.
AVDL's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AVDL is cheaper than 73.44% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of AVDL to the average of the S&P500 Index (22.10), we can say AVDL is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 98
AVDL Price Earnings VS Forward Price EarningsAVDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVDL Per share dataAVDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

AVDL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AVDL's earnings are expected to grow with 88.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y82.67%
EPS Next 3Y88.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVDL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVADEL PHARMACEUTICALS

NASDAQ:AVDL (3/7/2025, 8:06:15 PM)

After market: 7.91 0 (0%)

7.91

+0.03 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03 2025-03-03/bmo
Earnings (Next)05-06 2025-05-06/bmo
Inst Owners85.39%
Inst Owner Change6.75%
Ins Owners4.82%
Ins Owner Change2.21%
Market Cap716.46M
Analysts85
Price Target17.95 (126.93%)
Short Float %12.01%
Short Ratio6.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.29%
Min EPS beat(2)-20.15%
Max EPS beat(2)46.72%
EPS beat(4)2
Avg EPS beat(4)-0.8%
Min EPS beat(4)-41.55%
Max EPS beat(4)46.72%
EPS beat(8)2
Avg EPS beat(8)-19.68%
EPS beat(12)2
Avg EPS beat(12)-32.94%
EPS beat(16)5
Avg EPS beat(16)-22.24%
Revenue beat(2)1
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-1.22%
Max Revenue beat(2)0.9%
Revenue beat(4)3
Avg Revenue beat(4)2.74%
Min Revenue beat(4)-1.22%
Max Revenue beat(4)8.41%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.35%
PT rev (3m)-25.42%
EPS NQ rev (1m)8.11%
EPS NQ rev (3m)-413.53%
EPS NY rev (1m)-6.59%
EPS NY rev (3m)-83.5%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)-7.05%
Revenue NY rev (1m)-0.46%
Revenue NY rev (3m)-14.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 98
P/S 4.24
P/FCF N/A
P/OCF N/A
P/B 9.7
P/tB 12.57
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)0.08
Fwd EY1.02%
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS1.87
BVpS0.82
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.73%
ROE -66.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.97%
FCFM N/A
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
F-Score4
Asset Turnover1.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.75
Quick Ratio 2.33
Altman-Z -1.21
F-Score4
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)15.99%
Cap/Depr(5y)11.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.76%
EPS Next Y115.52%
EPS Next 2Y82.67%
EPS Next 3Y88.5%
EPS Next 5Y46.24%
Revenue 1Y (TTM)504.79%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%159.14%
Revenue Next Year48.16%
Revenue Next 2Y40.08%
Revenue Next 3Y33.31%
Revenue Next 5Y26.01%
EBIT growth 1Y69.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year292.64%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y63.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.5%
OCF growth 3YN/A
OCF growth 5YN/A